All In Biotech

Drug Trial Radar · NCT01266850

Safety and Immunogenicity of Sequential Rotavirus Vaccine Schedules

Safety and Immunogenicity of Sequential Rotavirus Vaccine Schedules With RotaTeq® and Rotarix®

Last checked: Nov 20, 2026Latest source record: Oct 28, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 1,384 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,384

Actual

Start

Mar 2011

Primary completion

Oct 2013

Study completion Mar 2014

Sponsor

Sponsor type
NIH
First posted
Dec 24, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Prevention
Who can join
All sexes, from 6 weeks, up to 14 weeks
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Rotavirus, sometimes called the "stomach flu," is the most common cause of severe diarrhea in children. Vaccines can prevent many types of infections and work by causing the body to make proteins called antibodies that fight infection. For some vaccines, more than one vaccination is needed so that the body will make enough antibodies to fight infection. The vaccines (RotaTeq® or Rotarix® oral vaccines) given in this study are recommended for infants by the Centers for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practices (ACIP). These vaccines require either 2 or 3 vaccinations to be effective. Healthy infants between 6 weeks and 14 weeks, 6 days of age at Visit 1 will participate for about 10-12 months. Study procedures include reaction assessment and blood sample.

Conditions

  • Rotavirus Infection

Interventions

  • Rotarix®Biological

    Each 1-mL dose of Rotarix® contains a suspension of at least 10\^6 median Cell Culture Infective Dose (CCID50) of live, attenuated human G1P rotavirus after reconstitution. The lyophilized vaccine contains amino acids, dextran, Dulbecco's Modified Eagle Medium (DMEM), sorbitol, and sucrose. The liquid diluent contains calcium carbonate, sterile water, and xanthan. The diluent includes an antacid component (calcium carbonate) to protect the vaccine during passage through the acid environment of the stomach. Rotarix® contains no preservatives. Once reconstituted, the vaccine will appear white and turbid.

  • RotaTeq®Biological

    2-mL ready-to-use oral solution of live reassortant rotaviruses, containing G1, G2, G3, G4, and P1A, which contains a minimum of 2.0 to 2.8 x 10\^6 infectious units (IU) per individual reassortant dose, depending on the serotype, and not greater than 116 x 10\^6 IU per aggregate dose. The buffered stabilizer solution contains sucrose, sodium citrate, sodium phosphate monobasic monohydrate, sodium hydroxide, polysorbate 80, cell culture media, and trace amounts of fetal bovine serum. RotaTeq® contains no preservatives. RotaTeq® is a pale yellow clear liquid that may have a pink tint.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants Developing a Serum Anti-rotavirus Immunoglobulin (Ig) A Titer of 20 or Greater in the WC3 IgA AssayTime frame: 3-6 weeks after the last vaccination
  2. Number of Participants Developing a Serum Anti-rotavirus Immunoglobulin (Ig) A Titer of 20 or Greater in the 89-12 IgA AssayTime frame: 3-6 weeks after the last vaccination
  3. Geometric Mean Serum Anti-rotavirus IgA TiterTime frame: 3-6 weeks after the last dose of vaccine

Locations

13 sites in 1 country. Site status is shown where the registry gives one.

  • Kaiser Permanente Vaccine Study Center

    Oakland, California

  • Children's Hospital & Research Center Oakland - Primary Care Clinic

    Oakland, California

  • Emory Children's Center - Pediatric Infectious Diseases

    Atlanta, Georgia

  • University of Iowa - Vaccine Research & Education Unit

    Iowa City, Iowa

  • University of Maryland School of Medicine - Center for Vaccine Development - Baltimore

    Baltimore, Maryland

  • Children's Mercy Hospital and Clinics - Infectious Diseases

    Kansas City, Missouri

  • Duke Translational Medicine Institute - Clinical Vaccine Unit

    Durham, North Carolina

  • Primary Physicians Research Inc. - Pittsburgh

    Pittsburgh, Pennsylvania

  • Vanderbilt University - Pediatric - Vanderbilt Vaccine Research Center

    Nashville, Tennessee

  • The University of Texas Medical Branch - Sealy Center for Vaccine Development (SCVD)

    Galveston, Texas

  • Baylor College of Medicine - Molecular Virology and Microbiology

    Houston, Texas

  • Group Health Research Institute - Seattle

    Seattle, Washington

  • Seattle Children's Hospital - Infectious Diseases

    Seattle, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.